Skip to content
2000
Volume 6, Issue 4
  • ISSN: 1573-3947
  • E-ISSN: 1875-6301

Abstract

Apoptosis plays an essential role in the processes of eukaryotic cellular homeostasis, and is thought to be a contributing factor in the development of a variety of pathologies including cancer. Knowledge of the molecular mechanisms and mediators of apoptosis, coupled with the fact that many current anticancer therapies function by activating apoptosis, has led to realization that apoptotic processes not only serve as the crucial regulators of carcinogenesis but are also critical determinants in therapy responses. Defects in apoptosis signaling often lead to ineffective response to anti-cancer therapeutics in the clinic and contribute to development of drug-resistant phenotype. The mediators of apoptosis, therefore, are attractive and rational targets for design and development of apoptosis-promoting strategies to combat cancer. Here we present an overview of different approaches and proof-of-principle evidence for identification, development, and use of agents that target apoptosis signaling in cancer. A synopsis of different apoptosis pathways and the agents, currently in the clinic or in development pipeline, that target mediators of apoptosis is presented. Last, but not least, novel and emerging apoptosis signaling targets with potential utility in anti-cancer drug development are also discussed.

Loading

Article metrics loading...

/content/journals/cctr/10.2174/157339410793358075
2010-11-01
2025-09-02
Loading full text...

Full text loading...

/content/journals/cctr/10.2174/157339410793358075
Loading

  • Article Type:
    Research Article
Keyword(s): 5-Aza-2'-deoxycytidine; actinomycin D; ANTI-APOPTOTIC BCL-2 FAMILY; anti-apoptotic Bcl-2 proteins; anti-cancer drug development; Anti-Cancer Therapeutics; Apoptosis; Apoptosis Signaling Pathways; apoptosis-promoting strategies; BH3Is; BIR3 antagonists; Caenorhabditis elegans; carcinogenesis; CARP-1; CARP-1 expression; caspase-independent cell death; Caspases; cell membrane blebbing; cell shrinkage; Chelerythrine; chromatin condensation; cIAP1 and cIAP2 genes; cisplatin; cyclin-dependent kinase; cyclooxygenase-2 inhibitors; Cytochrome; Death Receptors; decoy receptors; doxorubicin; drug-resistant phenotype; ectodysplasin A receptor; effector/executioner caspases; Embelin; etoposide; eukaryotic cellular homeostasis; extracellular receptor-activated pathway; EXTRINSIC PATHWAY; FADD-like interleukin-1β-converting enzyme inhibitory protein; FLIP expression; granzymes; HGS-ETR1; IAP-binding motif; IAPs; IFN-γ; inhibitor of apoptosis; intrinsic apoptosis pathway; ionizing radiation; LY2181308; Mitochondria; mitochondria-mediated pathway; mitochondrial outer membrane permeability; NF-kB activation; nucleosomal fragmentation; Nur77; Oblimersen; Omi/HtrA2; p53; PPARα ligands; protease-activating factor 1; radiotherapy; reactive oxygen species; RGD peptides; SAHBs; second mitochondria-derived activator of caspase; serpin; Smac/DIA-BLO; small-cell lung cancer; survivin; TNF-dependent signaling; TNF-related apoptosisinducing ligand; TRAIL stimulated apoptosis; tumor necrosis factor; tumor suppressor p53; TWX024; vIAPs; viral FLICE; X-Glu-X-Asp; zymogens
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test